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Abstract
Therapeutic retroviral vector integration near the oncogene LMO2 is thought to be a cause of
leukemia in X-SCID gene therapy trials. However, no published studies have evaluated the
frequency of vector integrations near exon 1 of the LMO2 locus. We identified a high incidence
region (HIR) of vector integration using PCR techniques in the upstream region close to the LMO2
transcription start site in the TPA-Mat T cell line. The integration frequency of the HIR was one
per 4.46 × 104 cells. This HIR was also found in Jurkat T cells but was absent from HeLa cells.
Furthermore, using human cord blood-derived CD34+ cells we identified a HIR in a similar region
as the TPA-Mat T cell line. One of the X-linked severe combined immunodeficiency (X-SCID)
patients that developed leukemia after gene therapy had a vector integration site in this HIR.
Therefore, the descriptions of the location and the integration frequency of the HIR presented here
may help us to better understand vector-induced leukemogenesis.
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Findings
The IL2RG gene encodes the interleukin-2 receptor γ chain
(IL-2Rγ) [1], and mutations in this gene cause X-linked
severe combined immunodeficiency (X-SCID) [2]. Gene
therapy trials for X-SCID have achieved remarkably suc-
cessful outcomes [3-5] but have also been associated with
leukemogenesis in some patients. Analyses of leukemic
cell clones from these patients revealed that the murine
leukemia virus (MLV) vector had integrated proximal to
the promoter of an oncogene involved in T-cell acute lym-
phoblastic leukemia, LIM-only protein 2 (LMO2), resulting
in aberrant expression. These findings suggest that retrovi-
ral vector integration near the LMO2 promoter is the most
likely cause of leukemogenesis in these cases [6-8]. Several
oncogenes, including LMO2, have very recently been
reported to be target genes for vector integration in two
patients that developed leukemia following retroviral-
mediated gene therapy [9,10]. Accordingly, a determina-
tion of the frequency of vector integration near the tran-
scription start site (TSS) of LMO2 would be important for
understanding the mechanism of the LMO2 insertional
mutagenesis observed in the leukemic cell clones. The fre-
quency of vector integrations near the TSS of the LMO2
locus has not been previously described. In the present
study, we have detected a region where vectors integrated
with high frequency near the TSS of the LMO2 locus in
two T cell lines and human cord blood-derived CD34+
cells, and we have subsequently determined the frequency
of this vector integration in TPA-Mat and CD34+ cells.
We previously identified 340 integration sites and 15 inte-
gration hotspots (defined as ≥ 3 integration sites within a
100-kb region) for MLV vector integration in infected
human T cell line clones [11]. A hotspot in intron 2 of the
TRAF2- and NCK-interacting kinase (TNIK) gene had three
integration sites within 3.5-kb, indicating that this
hotspot is an appropriate locus for estimating the integra-
tion frequency. We selected clone 705-9, which has an
integrated vector in the hotspot region of the TNIK locus
[11]. We investigated the sensitivity of the PCR techniques
utilized in this study. One copy of the junction sequence
between the virus gene and the TNIK gene was amplified
from DNA harvested from 705-9 cells, in the presence of
1 μg (1.5 × 105 cells) of genomic DNA from parental TPA-
Mat-ecoR cells. A nested PCR using a 3' LTR-specific
primer and a TNIK-specific primer showed that one copy
of the integrated vector was detectable as a 1.5-kb PCR
product (data not shown), demonstrating the sensitivity
of this assay.
To estimate the integration frequency in a human T cell
line, TPA-Mat-ecoR cells expressing the ecotropic mouse
receptor were infected with an ecotropic MLV vector that
encoded green fluorescent protein (GFP); the infection
efficiency (29 - 46%, based on GFP fluorescence) was sim-
ilar to that measured in patients in the gene therapy trials
[12]. At 48 hours post-infection, genomic DNA was iso-
lated from the cells. This acute infection system is suitable
for analyzing the distribution of initial vector integration.
The combinations of LTR- and TNIK- or LMO2-specific
primers (Additional file 1) used for the PCR reactions are
shown in Figure 1A. All resulting PCR products from 186
PCR amplifications (1 μg DNA was used for each PCR
amplification, and 186 μg of sample DNA correspond to
approximately 2.8 × 107 cells) carried out using LTR- and
TNIK-specific primers were cloned and sequenced, and 55
integration sites were mapped within the human genome
(Figure 1B and Additional files 2 and 3). For 1613 PCR
amplifications (1613 μg of sample DNA corresponds to
approximately 2.4 × 108 cells) using LTR- and LMO2-spe-
cific primers, 65 integration sites were unevenly distrib-
uted in an approximately ± 3-kb region surrounding exon
1 of LMO2 in the human genome (Figure 1C and Addi-
tional files 2 and 3). We found a high incidence region
(HIR) of vector integration in the region upstream of -
1740, near the LMO2 promoter (Figure 1C). A HIR was
also observed around the 705-9 cell integration site of the
TNIK locus. To confirm the HIR location in the LMO2
locus, we performed additional PCR assays in the region
upstream of -3000. Since no integration into the region
upstream of -3001 was detected with the indicated prim-
ers (Figure 1C and Additional files 2 and 3), we suggest
that the HIR in the TPA-Mat-ecoR cells ranges from -1740
(the downstream edge) to -3001 (the upstream edge). We
observed multiple-hit integrations that included two or
three vector integrations at the same nucleotide position
within this HIR of LMO2, as described below. In contrast,
no integration was detected downstream (1 ~1500) of
exon 1 (0/270) and only a few integrations were found
from 1500 to 3000 (3/270). Subsequent analysis using
the same primer sets in a second T cell line, Jurkat-ecoR
(infection efficiency: 28-36%, based on GFP fluorescence)
identified a HIR (-1801 to -2968) in a similar region as the
TPA-Mat-ecoR cells. No other integration sites near the
LMO2 promoter were detected in Jurkat-ecoR cells (Figure
1D and Additional files 2 and 3).
In a previous report, we found fewer hotspots in HeLa
cells than in TPA-Mat cells [11,13]. In addition, almost
none of the genes present in hematopoietic stem cell
hotspots were found in HeLa cell hotspots [14], suggest-
ing that hotspots in these different cell types are distinct.
We examined vector integration near the TSS of the LMO2
locus in HeLa cells to address this point. Only a few inte-
grations were observed upstream (-1 ~-3000; 3/540) and
downstream (1 ~3000; 1/540) of exon 1 (Figure 1E, Addi-
tional files 2 and 3) despite the high infection efficiency of
HeLa cells (45 ~58% based on GFP fluorescence). Real-
time PCR showed that the vector integration copy number
in TPA-Mat-ecoR cells (infection efficiency; 42%, basedRetrovirology 2009, 6:79 http://www.retrovirology.com/content/6/1/79
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Figure 1 (see legend on next page)
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on GFP fluorescence) was estimated at 2.0 per diploid
genome when normalized to interferon γ DNA, or 2.3 per
diploid genome according to the 42% GFP fluorescence in
the standard curve based on the real-time PCR analyses
(Additional file 4). The vector integration copy number in
HeLa cells was estimated at 1.4 per diploid genome
according to the 45% GFP fluorescence in the standard
curve based on the real-time PCR analyses (Additional file
4). The three upstream integration sites (-1740, -1875 and
-2068) in HeLa cells were also found in TPA-Mat-ecoR
cells with the -1875 integration site also present in Jurkat-
ecoR cells (Additional file 3). In the -1740 and -1875 inte-
gration sites of the TPA-Mat-ecoR cells, we observed two
and three integrated vectors, respectively. All multiple-hit
integrations listed in Additional file 3 were derived from
independent infection experiments. A previous study
demonstrated that the integration sites of MLV vectors
showed a weak favoring of active transcription units [15].
To examine whether endogenous LMO2 mRNA-levels cor-
related with the frequency of vector integration, we ana-
lyzed transcription of the LMO2 gene in TPA-Mat, Jurkat,
HeLa and the LMO2 expressing K562 cells [16]. Reverse
transcriptase (RT)-PCR showed that endogenous tran-
scription of the LMO2 gene was only detected in K562
cells (Figure 2A). Thus, the frequency of vector integration
in TPA-Mat, Jurkat and HeLa cells is not influenced by the
endogenous LMO2 mRNA-level.
Subsequently, we examined whether vector integration
would affect LMO2 expression in TPA-Mat-ecoR cells.
Endogenous LMO2 mRNA was not detected after vector
infection (100%, based on GFP fluorescence) in TPA-Mat-
ecoR cells (Figure 2A). We then prepared a series of luci-
ferase reporter gene constructs containing the region
between -3020 and +147 of the LMO2 promoter region.
The construct pGL3lmo2 (3020) containing the region (-
3020 ~+147) was virtually silent compared with the
pGL3-basic construct containing a SV40 promoter only
(Figure 2B). The insertion of the MLV LTR into a site (-
1798) within the HIR, where forward or reverse orienta-
tion of the inserted vector was observed (Additional file
3), resulted in significant increases in reporter gene activ-
ity. A similar result was obtained by the insertion into
another site (-2965), which is an integration site reported
in the leukemia patient. Consequently, these results sug-
gest that vector integration at -1798 within the HIR may
increase transcriptional activity of the LMO2 gene, similar
to the report for vector integration at -2965 in the leuke-
mia patient [12].
We compared the integration pattern in the TPA-Mat-ecoR
cells with the integration sites identified in patients (Pt) 4
and 5 who developed leukemia during the gene therapy
trials for treatment of X-SCID [12,17]. Vector integration
into the position detected in Pt4 (Figure 1C) was rare in
TPA-Mat-ecoR cells; differences in the integration frequen-
cies between the upstream (-1 ~-3000; 60/533) and
downstream (1 ~3000; 3/540) regions of exon 1 (Figure
1C) were observed. In contrast, the integration site (-
2965) in Pt5 was located in the HIR (-1740 ~-3001) (Fig-
ure 1C). Since CD34+ hematopoietic stem cells have been
infected with the MLV vector in the clinical trials, we
investigated whether the HIR is found in human CD34+
hematopoietic stem cells. Using the same primer sets in
umbilical cord blood CD34+ cells (infection efficiency:
14.7%, based on GFP fluorescence), we have identified an
HIR (-1882 to -2971) (18/270) in a similar region as the
TPA-Mat-ecoR and Jurkat-ecoR cells (Figure 1F, Addi-
MLV vector integrations into the TNIK and LMO2 gene loci Figure 1 (see previous page)
MLV vector integrations into the TNIK and LMO2 gene loci. (A) Schematic representation of MLV vector integration 
into a gene locus. MLV vector integrations were detected using nested PCR with a combination of 3' or 5' LTR-specific primers 
(3' L1L2 or 5' L1L2) and gene-specific primers (F or R). (B) MLV integration sites in the integration hotspot of the TNIK gene 
locus. Upper: Diagrammatic representation of the TNIK gene locus. Exons and the transcription start site are shown as Ex and 
+1, respectively. Lower: MLV vectors integrated into an approximately 2-kb region within the TNIK hotspot were detected by 
PCR with combinations of MLV vector-specific primers (3' L1L2 or 5' L1L2) and TNIK-specific primers (F1F2 or R1R2), as 
described in (A). The numbers indicate the nucleotide distance from the TNIK-specific primers (F1F2 or R1R2). The PCR prod-
ucts were sequenced, and the locations of the integration sites were determined by use of the human BLAST program. The 
integration site within the 705-9 cell hotspot was identified in our previous study [11] (large black arrowhead). (C) MLV inte-
gration sites near exon 1 of the LMO2 gene in TPA-Mat cells. Upper: Diagrammatic representation of the LMO2 gene locus. 
Lower: MLV vectors integrated into an approximately. ± 3-kb region from the transcription start site of LMO2 were detected 
by PCR with combinations of MLV vector-specific primers (3' L1L2 or 5' L1L2) and LMO2-specific primers (F3F4, F5F6, F7F8, 
R3R4, R5R6 or R7R8), as described in (B). The numbers indicate the nucleotide distance from the transcription start site. Pt4 
and Pt5 indicate the therapeutic MLV vector integration sites in patients 4 and 5, respectively, who developed leukemia after 
the French X-SCID gene therapy trials. (D) MLV integration sites near exon 1 of the LMO2 gene in Jurkat-ecoR cells. (E) MLV 
integration sites near exon 1 of the LMO2 gene in HeLa cells. (F) MLV integration sites near exon 1 of the LMO2 gene in human 
CD34+ cells. Black and white arrowheads respectively denote the reverse and forward orientation, relative to transcription, of 
the integrated MLV vectors.Retrovirology 2009, 6:79 http://www.retrovirology.com/content/6/1/79
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Figure 2 (see legend on next page)
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tional files 2 and 3). Only a few integrations were found
from 1 to -1500 (2/270) (Figure 1F, Additional files 2 and
3). Thus, analyzing the location of the HIR in hematopoi-
etic stem cells in these patients will provide insights into
leukemogenic integration sites and may have an impact
on future gene therapy trials. The HIR is also a suitable
region for analyzing the molecular mechanism of vector
integration with target-site preferences [14,18]. On the
other hand, results showing retroviral integration sites 35
kb upstream [10] and 10.6 kb downstream [9] of the TSS
were reported in the patients, and sites 36.3 kb, 69.2 kb,
68.0 kb, 68.3 kb and 0.9 kb upstream of the LMO2 TSS
were detected in a murine leukemia model [19]. This indi-
cates that integrations in the sites or regions which are far
from the TSS are closely associated in LMO2-related leuke-
mogenesis. Analysis of the differences and similarities
between the HIR near the TSS and the regions far from the
TSS will therefore facilitate the elucidation of LMO2-
related leukemogenesis in the future and may identify
additional HIRs that may exist far from the TSS.
We have attempted to estimate the number of cells that
carried an integrated vector in the HIR near exon 1 of the
LMO2 locus in the leukemia patients who participated in
the gene therapy trials for treatment of X-SCID [12]. The
integration frequencies calculated from the HIR data on
the TNIK and LMO2 loci were one per 4.18 × 104 cells and
one per 4.46 × 104 cells (or one per 1.992 × 105 integra-
tions and one per 2.125 × 105 integrations), respectively
(Figure 3, Additional files 4 and 5). This estimate was cal-
culated using the integration frequency data for the HIR
that was obtained in the TPA-Mat-ecoR cells as calculated
in Figure 3. 133 × 106 transduced cells were infused into
Pt5 [12] in the gene therapy trial. Given that at least 1% of
the transduced cells could give rise to T cells [12], Pt5
would have received 30 HIR-targeted cells, which suggests
that the frequency of vector integration in the HIR found
in TPA-Mat-ecoR cells may have contributed to the
observed leukemogenesis in Pt5 in the X-SCID gene ther-
apy trial. Furthermore, we have attempted to estimate the
integration frequency of CD34+ cells. The integration fre-
quency of CD34+ cells calculated from the HIR data based
on the vector integration copy number of CD34+ and TPA-
Mat cells was estimated to be one per 9.00 × 104 integra-
tions or one per 1.89 × 104 cells (Additional file 5). Our
estimation for the integration frequency of the HIR sug-
gested that a patient has a substantial chance that the
transfused cells would have the vector integration in the
HIR near the LMO2. However, not every patient develops
leukemia and leukemia development takes several years
to occur. Additional factors, such as mutations in other T-
cell oncogenes or additional insertional mutagenesis, can
contribute to leukemogenesis and were observed in the
leukemia patients [12] and murine leukemia model
[19,20]. Although there is controversy about the contribu-
tion of the therapeutic IL2RG gene in the leukemogenesis
[6,7,19], if the activation of only two genes, LMO2 and
the IL2RG, were enough to induce leukemia, more of the
patients would have developed leukemia in light of our
estimation for the integration frequency and the reports
that there are hotspots in the LMO2 locus [14,21]. Thus
three or four factors may be needed for leukemogenesis,
and the use of retroviral vectors without a tendency to
form HIRs near the LMO2 locus may improve the safety of
gene therapy.
In conclusion, the identification of the HIR near exon 1 of
the LMO2 locus in the T cell lines and human CD34+ cells
may partially explain the mechanism responsible for the
LMO2-insertional mutagenesis observed in leukemic cell
clones. It may help us to better understand vector-induced
leukemogenesis.
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Vector integration frequencies in the high incidence regions of the LMO2 and TNIK gene loci Figure 3 (see previous page)
Vector integration frequencies in the high incidence regions of the LMO2 and TNIK gene loci. MLV vectors inte-
grated in the HIR of the TNIK (open circles) and LMO2 (closed circles) gene loci were detected by PCR with combinations of 
MLV vector-specific primers (3' L1L2) and gene-specific primers (F1F2 or R5R6) using extracted DNA samples from MLV-
infected cells as template. Our results indicate that 42% of these MLV-infected cells expressed GFP. The number of vector 
integrations represents the number of detected integrations per 15 PCR amplifications, as calculated by Poisson distribution 
analyses. Each data set gave straight lines fitted by a linear approximation with a correlation coefficient (TNIK: R2 = 0.978; 
LMO2: R2 = 0.977). The calculated frequencies, according to each line, were one per 1.992 × 105 cells (TNIK) and 2.125 × 105 
cells (LMO2). The frequencies of vector integration into the HIRs of the TNIK and LMO2 genes, which were calculated using 
data based on Poisson distribution analyses, were one per 4.18 × 104 cells (1.992 × 105 cells (based on Poisson distribution 
analyses) × 0.42 (% of GFP positive cells)/2 (3' LTR primer direction/3' and 5' LTR primer directions)) and one per 4.46 × 104 
cells(2.125 × 105 cells (based on Poisson distribution analyses) × 0.42 (% of GFP positive cells)/2 (3' LTR primer direction/3' and 
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